Table of Contents Author Guidelines Submit a Manuscript

A corrigendum for this article has been published. To view the corrigendum, please click here.

Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 2565169, 9 pages
Research Article

Effects of Shenfu Injection in the Treatment of Septic Shock Patients: A Multicenter, Controlled, Randomized, Open-Label Trial

1Emergency Department, Peking Union Medical College Hospital, Beijing 100730, China
2Emergency Department, Beijing Hospital of the Ministry of Health, Beijing 100005, China
3Emergency Department, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China
4Emergency Department, Zhongda Hospital, Dongnan University, Nanjing 210009, China
5Emergency Department, Hubei Provincial Hospital, Wuhan 430000, China
6Emergency Department, The First Affiliated Hospital of Huaxi Medical College of Sichuan University, Chengdu 610044, China
7Emergency Department, Xinhua Hospital, Shanghai Jiao Tong University, Shanghai 200093, China
8Emergency Department, Saint Louis University, Saint Louis, MO 63130, USA
9Emergency Department, The First Affiliated Hospital of Kunming Medical University, Kunming 650034, China
10Emergency Department, PLA 263 Hospital, Beijing 101199, China

Received 4 February 2016; Revised 13 May 2016; Accepted 7 June 2016

Academic Editor: Kenji Watanabe

Copyright © 2016 Yi Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The effect of Shenfu on biochemical parameters and survival during resuscitation in patients with septic shock was examined. This was a multicenter, controlled, randomized, open-label trial carried out in 210 patients with septic shock from seven medical centers in China. They were randomized to Shenfu or saline. The primary outcome was lactate clearance. The secondary outcomes were shock index normalization, dose of vasopressors, ICU stay, hospital stay, and mortality. A total of 199 patients completed the trial. Blood pressure, heart rate, and other routine lab tests showed no difference between the groups. Lactate levels and lactate clearance were similar between the two groups. Hospital and ICU stay were similar between the two groups. When considering all patients, the 7- and 28-day mortality were similar between the two groups, but when considering only patients with lactate levels ≥4.5 mmol/L, the Shenfu group showed a better 7-day survival than the control group (7 days: 83.3% versus 54.5%, ; 28 days: 72.7% versus 47.6%, ). Shenfu may improve the 7-day survival in patients with impaired lactate clearance (≥4.5 mmol/L), but the mechanism for this effect is unclear. Additional studies are necessary to characterize the hemodynamic changes after Shenfu infusion. This trial is registered with ChiCTR-TRC-11001369.